Clinical Approach to Erectile Dysfunction
Comprehensive Practical Framework1. Symptom Overview
Understanding the clinical significance and classification of erectile dysfunction
Erectile dysfunction is one of the most common sexual health complaints in men, affecting approximately 30 million men in the United States alone. Global prevalence estimates suggest that over 150 million men worldwide are affected, with this number projected to exceed 300 million by 2025. The Massachusetts Male Aging Study demonstrated that the prevalence increases dramatically with age: approximately 40% of men are affected at age 40, rising to nearly 70% by age 70. Despite its high prevalence, erectile dysfunction remains significantly underdiagnosed and undertreated, with fewer than 25% of affected men seeking medical care.
Definition
Erectile dysfunction is defined as the persistent or recurrent inability to achieve and/or maintain an erection sufficient for satisfactory sexual performance. According to the International Society for Sexual Medicine, symptoms must be present for at least 3 months to establish the diagnosis, except in cases following trauma or surgery where the diagnosis can be made earlier. It is important to distinguish erectile dysfunction from other sexual disorders such as decreased libido, premature ejaculation, or anorgasmia, though these conditions frequently coexist.
Classification by Duration
| Category | Duration | Common Causes | Clinical Significance |
|---|---|---|---|
| Acute/Situational | Less than 1 month | Performance anxiety, stress, fatigue, alcohol use, relationship conflict | Often self-limiting; may not require treatment if single episode; reassurance often sufficient |
| Recent Onset | 1 to 3 months | New medication, acute illness, new psychosocial stressor, hormonal changes | Warrants investigation; medication review essential; may represent early organic disease |
| Chronic/Established | Greater than 3 months | Vascular disease, diabetes mellitus, neurological disorders, hypogonadism, chronic psychological conditions | Meets diagnostic criteria; comprehensive evaluation required; often indicates underlying systemic disease |
Classification by Onset Pattern
Primary Erectile Dysfunction
The patient has never been able to achieve or maintain an erection sufficient for intercourse. This presentation is rare, accounting for less than 10% of cases, and suggests congenital anatomical abnormalities, severe psychological factors from early development, or significant hormonal disorders present since puberty. These patients often require specialist referral for comprehensive evaluation.
Secondary Erectile Dysfunction
The patient previously had normal erectile function that has subsequently deteriorated. This is the most common presentation, accounting for over 90% of cases. Secondary erectile dysfunction may develop gradually (suggesting vascular or metabolic causes) or suddenly (suggesting psychogenic, neurological, or medication-related causes).
Classification by Severity
| Severity | Description | Clinical Features |
|---|---|---|
| Mild | Occasional difficulty achieving or maintaining erection | Erections achieved with additional stimulation; morning erections present; successful intercourse more than 50% of attempts |
| Moderate | Frequent difficulty with erections | Inconsistent response to stimulation; reduced morning erections; successful intercourse 25-50% of attempts |
| Severe/Complete | Unable to achieve any erection sufficient for penetration | Absent morning erections; no response to stimulation; unable to achieve intercourse |
Classification by Pattern and Context
| Pattern | Description | Suggests |
|---|---|---|
| Situational | Erectile dysfunction occurs only in specific circumstances (with partner but not with masturbation, or vice versa) | Psychogenic etiology; performance anxiety; relationship issues |
| Global | Erectile dysfunction occurs in all situations including masturbation and with any partner | Organic etiology; vascular, neurological, or hormonal cause |
| Partner-specific | Erectile dysfunction only with certain partners | Psychogenic factors; relationship dynamics; attraction issues |
| Progressive | Gradual worsening over months to years | Vascular disease; diabetes mellitus; aging-related changes |
| Sudden onset | Abrupt loss of erectile function | Psychogenic cause; new medication; acute neurological event; post-surgical |
Classification by Etiology
Organic (approximately 80%)
Vasculogenic: Atherosclerosis, diabetes, hypertension, dyslipidemia, pelvic trauma
Neurogenic: Spinal cord injury, multiple sclerosis, diabetic neuropathy, pelvic surgery
Hormonal: Hypogonadism, hyperprolactinemia, thyroid disorders
Anatomical: Peyronie’s disease, penile fibrosis
Psychogenic (approximately 10-20%)
Generalized: Depression, anxiety disorders, chronic stress
Situational: Performance anxiety, relationship conflict, partner-related issues
Traumatic: Sexual abuse history, prior negative sexual experiences
Mixed (very common)
Most cases of erectile dysfunction have both organic and psychogenic components. Organic disease often leads to performance anxiety, which further worsens erectile function. Always consider the psychological impact even when an organic cause is identified.
Key Concept: Erectile Dysfunction as a Sentinel Symptom
Erectile dysfunction is increasingly recognized as an early marker of systemic vascular disease. The penile arteries (1-2 mm diameter) develop atherosclerosis before larger coronary arteries (3-4 mm) and carotid arteries (5-7 mm). Studies show that erectile dysfunction precedes coronary artery disease symptoms by an average of 2-5 years. Men with erectile dysfunction have a 1.5 to 2-fold increased risk of cardiovascular events. Therefore, every patient presenting with erectile dysfunction should undergo cardiovascular risk assessment.
Impact on Quality of Life
Erectile dysfunction significantly affects psychological well-being and interpersonal relationships. Studies demonstrate that men with erectile dysfunction have higher rates of depression, anxiety, and reduced self-esteem. Partners of affected men also report decreased relationship satisfaction and sexual fulfillment. The bidirectional relationship between erectile dysfunction and psychological distress creates a cycle that must be addressed in comprehensive management.
2. Pathophysiology and Mechanisms
Understanding the underlying mechanisms of erectile dysfunction
Normal erectile function requires the coordinated integration of psychological, hormonal, neurological, and vascular systems. An erection is fundamentally a neurovascular event that depends on adequate arterial inflow, relaxation of corporal smooth muscle, and restriction of venous outflow. Understanding these mechanisms is essential for identifying the etiology in individual patients and selecting appropriate treatment.
Normal Erectile Physiology: The Erection Pathway
| Component | Structure | Function |
|---|---|---|
| Central Initiation | Cerebral cortex, limbic system, hypothalamus | Processes sexual stimuli (visual, auditory, olfactory, imaginative); initiates psychogenic erections |
| Spinal Integration | Thoracolumbar (T11-L2) and sacral (S2-S4) spinal cord segments | T11-L2: psychogenic pathway; S2-S4: reflexogenic pathway; integration of central and peripheral signals |
| Peripheral Nerves | Cavernous nerves (branches of pelvic plexus) | Release of neurotransmitters (acetylcholine, nitric oxide) to initiate smooth muscle relaxation |
| Vascular Supply | Internal pudendal artery → penile artery → cavernosal arteries → helicine arteries | Provides arterial inflow; helicine arteries open directly into sinusoidal spaces |
| Corporal Tissue | Corpora cavernosa (paired), corpus spongiosum | Smooth muscle relaxation allows sinusoidal filling; expansion compresses subtunical venules |
| Veno-occlusive Mechanism | Subtunical venules, tunica albuginea | Expanded sinusoids compress venules against rigid tunica; prevents venous outflow; maintains rigidity |
Molecular Mechanism of Erection
The Nitric Oxide-cGMP Pathway
- Sexual stimulation → parasympathetic activation → release of acetylcholine
- Acetylcholine → stimulates endothelial cells → release of nitric oxide (NO)
- Nitric oxide → diffuses into smooth muscle cells → activates guanylate cyclase
- Guanylate cyclase → converts GTP to cyclic guanosine monophosphate (cGMP)
- cGMP → activates protein kinase G → decreases intracellular calcium
- Decreased calcium → smooth muscle relaxation → sinusoidal filling → erection
- Phosphodiesterase type 5 (PDE5) → degrades cGMP → terminates erection
Key Molecular Targets and Clinical Relevance
Nitric Oxide
Source: Endothelial cells, non-adrenergic non-cholinergic (NANC) neurons
Function: Primary mediator of smooth muscle relaxation
Clinical relevance: Endothelial dysfunction (diabetes, atherosclerosis) reduces NO production; explains vascular erectile dysfunction
Phosphodiesterase Type 5
Location: Highly concentrated in penile smooth muscle
Function: Degrades cGMP, terminating the erectile response
Clinical relevance: PDE5 inhibitors (sildenafil, tadalafil) block cGMP degradation, enhancing and prolonging erections
Testosterone
Source: Leydig cells of the testes
Function: Maintains libido; supports nitric oxide synthase expression; maintains corporal smooth muscle health
Clinical relevance: Hypogonadism causes reduced libido and may impair erectile response to PDE5 inhibitors
How Conditions Cause Erectile Dysfunction
| Condition | Mechanism | Treatment Implication |
|---|---|---|
| Diabetes mellitus | Multifactorial: endothelial dysfunction → reduced NO; autonomic neuropathy → impaired nerve signaling; microangiopathy → reduced blood flow; accelerated atherosclerosis | Glycemic control essential; may require combination therapy; higher doses of PDE5 inhibitors often needed |
| Atherosclerosis/Cardiovascular disease | Reduced arterial inflow to penis; endothelial dysfunction impairs NO release; same process affecting coronary arteries affects penile arteries earlier due to smaller caliber | Cardiovascular risk factor modification; erectile dysfunction as opportunity for CV prevention; PDE5 inhibitors effective first-line |
| Hypertension | Chronic elevated pressure causes arterial wall damage; reduces arterial compliance; accelerates atherosclerosis; many antihypertensives also contribute | Blood pressure control important; consider switching to erectile-sparing antihypertensives (ARBs, CCBs, nebivolol) |
| Hypogonadism | Low testosterone reduces libido (primary effect); decreases NO synthase expression; leads to corporal fibrosis and smooth muscle atrophy over time | Testosterone replacement restores libido and may improve erectile response; essential to check before PDE5 inhibitor failure declared |
| Radical prostatectomy | Cavernous nerve injury (bilateral or unilateral); disruption of accessory pudendal arteries; psychological impact of cancer diagnosis | Nerve-sparing technique when oncologically safe; penile rehabilitation protocols; may require intracavernosal injections |
| Spinal cord injury | Disruption of psychogenic pathway (lesions above T11); reflexogenic erections may be preserved (intact S2-S4); loss of coordination between pathways | Level of injury determines erectile capability; reflexogenic erections with PDE5 inhibitors if sacral cord intact |
| Depression/Anxiety | Central inhibition of sexual arousal pathways; performance anxiety creates sympathetic overdrive which opposes parasympathetic erection pathway; medications contribute | Treat underlying condition; consider erectile-sparing antidepressants (bupropion, mirtazapine); psychosexual therapy |
| Venous leak | Failure of veno-occlusive mechanism; subtunical venules not adequately compressed; may be due to smooth muscle atrophy, Peyronie’s disease, or tunica albuginea abnormality | Often refractory to PDE5 inhibitors; may require constriction devices, intracavernosal injection, or surgery |
| Peyronie’s disease | Fibrous plaque formation in tunica albuginea; causes penile curvature; may impair veno-occlusive mechanism; pain during erection; psychological distress | Collagenase injections; surgical correction for stable disease; psychological support |
Understanding the Two Main Organic Pathways
Vasculogenic Erectile Dysfunction
Arterial insufficiency: Reduced inflow cannot fill sinusoidal spaces adequately. Associated with atherosclerosis, diabetes, hypertension, smoking, and dyslipidemia.
Veno-occlusive dysfunction: Blood flows in but cannot be retained. May be due to damaged tunica albuginea, smooth muscle atrophy, or fibrosis. Often seen in older men and those with Peyronie’s disease.
Key feature: Gradual onset over months to years; affects all situations equally.
Neurogenic Erectile Dysfunction
Central lesions: Stroke, Parkinson’s disease, multiple sclerosis affect brain or spinal cord pathways.
Peripheral neuropathy: Diabetes mellitus is the most common cause; damages cavernous nerves.
Surgical/traumatic: Pelvic surgery (prostatectomy, colorectal surgery), pelvic fracture with urethral injury.
Key feature: May be sudden onset if surgical/traumatic; progressive if neuropathic.
The Role of Hormones
| Hormone | Role in Erectile Function | Clinical Consequence of Abnormality |
|---|---|---|
| Testosterone | Maintains libido and sexual interest; supports penile tissue health; required for adequate NO synthase expression | Low testosterone: reduced libido (most prominent), possible reduced erectile response, impaired response to PDE5 inhibitors |
| Prolactin | Inhibits gonadotropin-releasing hormone; normally at low levels | Elevated prolactin: suppresses testosterone, causes reduced libido and erectile dysfunction; think pituitary adenoma |
| Thyroid hormones | Regulate overall metabolism; affect sex hormone-binding globulin levels | Hypothyroidism: fatigue, reduced libido; Hyperthyroidism: may cause premature ejaculation, occasionally erectile dysfunction |
| Estradiol | Present in small amounts in men; converted from testosterone by aromatase | Elevated estrogen (obesity, liver disease): may suppress testosterone, cause erectile dysfunction and gynecomastia |
Often Overlooked Mechanism: The Sympathetic-Parasympathetic Balance
Erection is a parasympathetic event, while ejaculation and detumescence are sympathetic events. Performance anxiety activates the sympathetic nervous system, releasing norepinephrine which causes smooth muscle contraction and opposes erection. This explains why psychogenic erectile dysfunction can occur even in men with intact vascular and neurological function. It also explains why beta-blockers (which reduce sympathetic tone) do not typically cause erectile dysfunction, while anxiety and stress clearly do. Understanding this balance is crucial for managing the psychological component of erectile dysfunction.
Nocturnal Penile Tumescence: A Physiological Window
Healthy men experience 3-5 erections during sleep, typically during rapid eye movement (REM) sleep phases. These nocturnal erections are centrally mediated and largely independent of psychological factors. The presence of morning erections (observed upon waking from REM sleep) suggests intact neurovascular function and points toward a psychogenic etiology for erectile dysfunction. Absence of nocturnal/morning erections suggests organic pathology. While formal nocturnal penile tumescence testing exists, simply asking about morning erections provides valuable diagnostic information.
3. History Taking
A comprehensive approach to eliciting the erectile dysfunction history
Red Flags — Require Urgent Evaluation
- Sudden painful erection lasting more than 4 hours — Priapism; urological emergency
- Penile curvature with pain — Active Peyronie’s disease; early intervention beneficial
- New neurological symptoms — Spinal cord pathology; cauda equina syndrome
- Symptoms of hypogonadism with visual disturbance or headache — Pituitary tumor compressing optic chiasm
- Erectile dysfunction with chest pain or exertional symptoms — Underlying coronary artery disease; cardiac evaluation before treatment
- Post-traumatic erectile dysfunction — Pelvic fracture, urethral injury; requires imaging
- Rapid onset with severe depression or suicidal ideation — Mental health crisis; prioritize psychiatric care
- Young patient with primary erectile dysfunction — Congenital abnormality or severe psychological trauma; specialist referral
Systematic History: The “ERECTION” Approach
Use the mnemonic “ERECTION” to ensure comprehensive history taking:
- E — Erection quality: Can you achieve an erection? How firm is it? Can you maintain it? Is it sufficient for penetration?
- R — Relationship and partner factors: How is your relationship? Is this problem situational or with all partners? What is your partner’s response?
- E — Early morning and nocturnal erections: Do you wake with erections? This helps differentiate organic from psychogenic causes.
- C — Chronology and course: When did this start? Was onset sudden or gradual? Has it worsened over time?
- T — Triggers and timing: Are there specific situations where it’s better or worse? Any relationship to stress, fatigue, or alcohol?
- I — Interest and libido: Is your desire for sex normal? Reduced libido suggests hypogonadism or depression.
- O — Other sexual functions: Any problems with ejaculation? Orgasm? Penile sensation? Pain during sex?
- N — Nexus with health: What other medical conditions do you have? What medications are you taking? Do you smoke, drink alcohol, or use recreational drugs?
Key Historical Features: Organic vs Psychogenic
| Feature | Suggests Organic Cause | Suggests Psychogenic Cause |
|---|---|---|
| Onset | Gradual, progressive over months to years | Sudden, often linked to specific event or stressor |
| Morning erections | Absent or significantly reduced | Present and normal |
| Erections with masturbation | Also impaired | Often preserved |
| Situational variation | Consistent across all situations | Variable; better in some situations than others |
| Libido | Often preserved (unless hypogonadism) | May be reduced; often associated with depression |
| Partner relationship | Less directly related | Often associated with relationship conflict |
| Comorbidities | Diabetes, cardiovascular disease, neurological disease present | Depression, anxiety, prior sexual trauma |
Targeted Questions by Suspected Cause
| Suspected Cause | Key Features | Ask This Question |
|---|---|---|
| Vasculogenic (atherosclerosis) | Gradual onset, cardiovascular risk factors, absent morning erections | “Do you have pain in your legs when walking that goes away with rest?” (claudication suggests peripheral vascular disease) |
| Diabetes mellitus | Progressive erectile dysfunction, may have neuropathy symptoms | “Do you have numbness or tingling in your feet? Any problems with bladder control?” (suggests diabetic neuropathy) |
| Hypogonadism | Reduced libido prominent, fatigue, decreased energy | “Has your interest in sex decreased? Do you feel more tired than usual? Have you noticed less beard growth or smaller testes?” |
| Hyperprolactinemia | Reduced libido, possible galactorrhea, visual symptoms | “Have you noticed any breast discharge? Any changes in your vision or persistent headaches?” |
| Neurogenic (spinal/peripheral) | History of back problems, surgery, or trauma | “Have you had any back surgery or spinal problems? Any difficulty with urination or bowel control?” |
| Post-surgical | Clear temporal relationship to pelvic surgery | “When exactly did the problem start relative to your surgery? Was nerve-sparing attempted?” |
| Peyronie’s disease | Penile curvature, pain with erection, palpable plaque | “Have you noticed any bend or curve in your penis when erect? Is there pain during erection?” |
| Psychogenic/Performance anxiety | Sudden onset, situational, preserved morning erections | “Do you feel anxious about sexual performance? Was there a specific event when this started?” |
| Depression | Reduced libido, anhedonia, sleep disturbance | “How has your mood been? Have you lost interest in activities you used to enjoy? How is your sleep?” |
| Medication-induced | Temporal relationship to starting new medication | “When did you start this medication relative to when the erectile problems began? Have any medications been changed recently?” |
Medication and Substance History
Medications That Commonly Cause Erectile Dysfunction
- Antihypertensives: Thiazide diuretics (most common), spironolactone, centrally-acting agents (clonidine, methyldopa), older beta-blockers (atenolol, metoprolol)
- Antidepressants: Selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants
- Antipsychotics: Particularly those causing hyperprolactinemia (risperidone, haloperidol)
- Antiandrogens: Finasteride, dutasteride, spironolactone, GnRH agonists, bicalutamide
- Opioids: Chronic use causes hypogonadism
- Histamine H2 blockers: Cimetidine (antiandrogen effect)
- Recreational drugs: Chronic alcohol, cannabis, cocaine, amphetamines
Medications Less Likely to Cause Erectile Dysfunction
- Antihypertensives: Angiotensin receptor blockers (may actually improve), calcium channel blockers, nebivolol
- Antidepressants: Bupropion (may improve), mirtazapine, trazodone
- Statins: Generally neutral; cardiovascular benefits outweigh any minimal effects
Substances and Lifestyle Factors
- Smoking: Major independent risk factor; dose-dependent effect; cessation improves function
- Alcohol: Acute intoxication impairs erection; chronic heavy use causes neuropathy and hypogonadism
- Cycling: Prolonged pressure on perineum can cause nerve and vascular damage
Psychosocial and Relationship History
Essential Psychosocial Questions
Many men find discussing sexual function difficult. Create a comfortable, non-judgmental environment. Consider these areas:
- Relationship status: Partnered or single? Duration of relationship? Satisfaction with relationship?
- Partner’s health: Does partner have any health conditions affecting intimacy? Postmenopausal dyspareunia?
- Communication: Have you discussed this with your partner? What is their response?
- Performance pressure: Do you feel pressure to perform? Fear of failure?
- Mental health: Screen for depression (PHQ-2/PHQ-9) and anxiety; these are highly comorbid
- Life stressors: Work stress, financial problems, family issues?
- Sexual history: History of sexual trauma? Cultural or religious beliefs affecting sexuality?
- Pornography use: Excessive use may create unrealistic expectations and desensitization
Validated Assessment Tools
| Tool | Description | Clinical Use |
|---|---|---|
| International Index of Erectile Function (IIEF) | 15-item questionnaire; gold standard for clinical trials; assesses erectile function, orgasmic function, sexual desire, intercourse satisfaction, overall satisfaction | Comprehensive assessment; useful for monitoring treatment response; erectile function domain (IIEF-EF) score categorizes severity |
| IIEF-5 (SHIM) | 5-item abbreviated version; Sexual Health Inventory for Men; score 1-25 | Quick screening in primary care; score 21 or less suggests erectile dysfunction; 17-21 mild, 12-16 moderate, less than 12 severe |
| Erection Hardness Score (EHS) | Single question: “How would you rate the hardness of your erection?” Score 1-4 | Very quick assessment; Grade 1 (larger but not hard), 2 (hard but not enough for penetration), 3 (hard enough for penetration but not fully), 4 (fully hard and rigid) |
Focused Review of Systems
Cardiovascular
- Chest pain or pressure with exertion
- Shortness of breath
- Claudication symptoms
- Previous cardiac events
Neurological
- Numbness or tingling (peripheral neuropathy)
- Back pain or sciatica
- Bladder or bowel dysfunction
- Tremor, gait disturbance
Endocrine
- Fatigue, decreased energy
- Hot flashes (hypogonadism)
- Polyuria, polydipsia (diabetes)
- Cold intolerance, weight changes (thyroid)
Urological
- Lower urinary tract symptoms
- Hematuria
- Testicular pain or masses
- Previous urological surgery
4. Physical Examination
A systematic approach to examining patients with erectile dysfunction
Systematic Framework: The physical examination in erectile dysfunction serves two purposes: (1) identifying potential causes of erectile dysfunction, and (2) assessing cardiovascular risk to ensure safe treatment. Use a “General → Cardiovascular → Genitourinary → Neurological” approach for complete evaluation.
General Inspection
- Body habitus: Obesity (associated with hypogonadism, diabetes, cardiovascular disease); central adiposity particularly significant
- Secondary sexual characteristics: Adequacy of facial hair, body hair distribution, muscle mass (reduced in hypogonadism)
- Gynecomastia: Suggests hypogonadism, hyperprolactinemia, or estrogen excess (liver disease, medications)
- Signs of chronic disease: Cushingoid features, acromegalic features, thyroid abnormalities
- Mood and affect: Signs of depression, anxiety during examination
Vital Signs
| Vital Sign | What to Look For | Clinical Significance |
|---|---|---|
| Blood Pressure | Elevated blood pressure; check in both arms if peripheral vascular disease suspected | Hypertension is major cardiovascular risk factor; also causes erectile dysfunction directly; important for treatment decisions |
| Heart Rate | Resting tachycardia or bradycardia; irregular rhythm | Arrhythmias may indicate cardiac disease; important for PDE5 inhibitor safety assessment |
| Body Mass Index | Calculate from height and weight; waist circumference | Obesity strongly associated with erectile dysfunction; central obesity (waist greater than 102 cm) indicates metabolic syndrome |
| Waist-to-Hip Ratio | Ratio greater than 0.9 in men | Indicates central adiposity and increased cardiovascular risk |
Cardiovascular Examination
Why Cardiovascular Assessment Is Essential
Erectile dysfunction and cardiovascular disease share common risk factors and pathophysiology. Sexual activity is equivalent to climbing 2-3 flights of stairs or walking briskly (3-5 metabolic equivalents). Patients must be assessed for cardiovascular fitness before initiating treatment, particularly PDE5 inhibitors.
Heart
- Auscultation: Murmurs (particularly aortic stenosis — contraindication to PDE5 inhibitors if severe)
- Rhythm: Irregular rhythm suggesting atrial fibrillation
- Signs of heart failure: Elevated jugular venous pressure, displaced apex, S3 gallop
Peripheral Vascular Assessment
- Femoral pulses: Diminished suggests aortoiliac disease (Leriche syndrome — triad of erectile dysfunction, claudication, absent femoral pulses)
- Distal pulses: Dorsalis pedis, posterior tibial — diminished indicates peripheral arterial disease
- Femoral bruits: Suggests atherosclerotic disease
- Ankle-brachial index: If peripheral vascular disease suspected; less than 0.9 is abnormal
- Lower extremity examination: Hair loss, shiny skin, cool temperature, poor capillary refill — signs of chronic ischemia
Abdominal Examination
- Central obesity: Measure waist circumference at level of iliac crest
- Hepatomegaly: May indicate liver disease causing increased estrogen and decreased testosterone
- Aortic aneurysm: Palpable pulsatile mass; aortic disease associated with erectile dysfunction
- Surgical scars: Previous pelvic or abdominal surgery (prostatectomy, colorectal surgery, aortic surgery)
- Inguinal regions: Hernias, lymphadenopathy
Genitourinary Examination
Examination Tips
Explain each step of the examination clearly. Ensure privacy and appropriate chaperone. A focused genital examination is essential but should be performed sensitively, recognizing that patients may feel embarrassed.
Penis
| Finding | Description | Conditions |
|---|---|---|
| Peyronie’s plaque | Palpable fibrous plaque along penile shaft, typically on dorsal surface | Peyronie’s disease; causes curvature and may impair veno-occlusion |
| Phimosis | Tight foreskin that cannot be retracted over glans | May cause pain with intercourse; can be associated with diabetes |
| Hypospadias | Urethral meatus located on ventral surface of penis | Congenital abnormality; rarely causes erectile dysfunction but may affect function |
| Penile size | Stretched penile length less than 7 cm may indicate micropenis | May suggest hypogonadism from early development |
| Skin changes | Lesions, discharge, balanitis | Infection; lichen sclerosus; malignancy (rare) |
Testes
| Finding | Description | Conditions |
|---|---|---|
| Small testes | Volume less than 15 mL or length less than 4 cm (use orchidometer if available) | Hypogonadism; Klinefelter syndrome; previous orchitis; atrophy from exogenous testosterone |
| Absent testis | Unilateral or bilateral absence | Previous orchidectomy; undescended testis |
| Testicular mass | Any palpable abnormality within testis | Testicular cancer (though rarely causes erectile dysfunction); requires urgent ultrasound |
| Varicocele | “Bag of worms” feel in scrotum, more prominent standing | May affect testosterone production; usually left-sided |
Digital Rectal Examination
- Prostate size: Benign prostatic hyperplasia common in age group affected by erectile dysfunction
- Prostate consistency: Hard nodules require further investigation to exclude malignancy
- Anal tone: Reduced tone may indicate neurological abnormality affecting sacral segments
- Bulbocavernosus reflex: Squeeze glans penis and feel for anal sphincter contraction; tests S2-S4 arc integrity
Neurological Examination
Focused Examination
| Test | Technique | Clinical Significance |
|---|---|---|
| Perineal sensation | Light touch and pinprick sensation in perineum (S2-S4 dermatomes) | Reduced sensation suggests sacral nerve or spinal cord pathology |
| Bulbocavernosus reflex | Squeeze glans; observe/palpate anal sphincter contraction | Absent reflex suggests sacral cord lesion or peripheral neuropathy; present in 70% of normal men |
| Cremasteric reflex | Stroke inner thigh; observe ipsilateral testicular elevation | Tests L1-L2 segments; absence may indicate upper motor neuron lesion |
| Lower limb reflexes | Knee jerk (L3-L4), ankle jerk (S1-S2) | Absent ankle jerks common in diabetic peripheral neuropathy |
| Peripheral sensation | Light touch, vibration sense in feet (128 Hz tuning fork) | Reduced vibration sense is early sign of diabetic neuropathy; “stocking” distribution |
Signs of Specific Neurological Conditions
- Parkinson’s disease: Tremor, rigidity, bradykinesia, masked facies
- Multiple sclerosis: Nystagmus, optic pallor, spasticity, sensory level
- Spinal cord pathology: Sensory level, upper motor neuron signs below lesion, bladder dysfunction
Signs of Endocrine Disorders
Hypogonadism
- Reduced facial and body hair
- Gynecomastia
- Small, soft testes
- Decreased muscle mass
- Increased body fat (especially abdominal)
- Fine facial wrinkles
Other Endocrine Conditions
- Hyperthyroidism: Tremor, lid lag, tachycardia, goiter
- Hypothyroidism: Dry skin, bradycardia, delayed reflexes, periorbital edema
- Cushing syndrome: Moon face, buffalo hump, striae, central obesity
- Acromegaly: Enlarged hands/feet, frontal bossing, prognathism
Expected Findings by Etiology
| Condition | General Appearance | Cardiovascular | Genitourinary/Neurological |
|---|---|---|---|
| Vasculogenic | Often obese; may appear older than stated age | Hypertension; diminished peripheral pulses; femoral bruits; signs of heart failure | Usually normal genitalia; neurological examination normal |
| Diabetic | May be obese or thin; acanthosis nigricans | Hypertension common; peripheral vascular disease signs | Reduced peripheral sensation; absent ankle reflexes; may have autonomic signs |
| Hypogonadism | Reduced body hair; gynecomastia; increased body fat | Usually normal | Small, soft testes; may have reduced muscle mass |
| Neurogenic (spinal) | May have motor deficits; wheelchair use | Usually normal | Sensory level; abnormal reflexes; bladder dysfunction signs |
| Peyronie’s disease | Normal | Normal | Palpable penile plaque; may have Dupuytren’s contracture (associated condition) |
| Psychogenic | May appear anxious or depressed | Normal | Completely normal examination |
Important Teaching Point
Normal examination is common! Many patients with erectile dysfunction, including those with vascular disease, diabetes, or psychogenic causes, will have an entirely normal physical examination. The examination helps identify specific causes and assess cardiovascular risk, but a normal examination does not exclude organic pathology. The history remains the most important diagnostic tool, and laboratory investigations are often needed to identify underlying causes.
Quick Examination Checklist
Minimum Examination for All Patients with Erectile Dysfunction:
- Blood pressure and BMI
- General appearance (secondary sexual characteristics, gynecomastia)
- Cardiovascular: heart sounds, femoral pulses, peripheral pulses
- Abdominal: waist circumference, surgical scars
- Genitalia: penis (plaques, abnormalities), testes (size, consistency)
- Focused neurological: peripheral sensation (feet), ankle reflexes
- Digital rectal examination if indicated (prostate symptoms, neurological concerns)
5. Differential Diagnosis
Systematic approach organized by probability and clinical features
Erectile dysfunction is a symptom with multiple potential underlying causes that frequently coexist. The differential diagnosis should be approached systematically, considering the most common causes first while remaining vigilant for less common but important etiologies. In most cases, the cause is multifactorial, combining organic and psychogenic components.
Initial Classification: Primary vs Secondary Erectile Dysfunction
Primary Erectile Dysfunction (less than 10%)
Patient has never achieved adequate erections. Consider:
- Congenital anatomical abnormalities
- Severe psychological factors from early development
- Congenital hypogonadism (Klinefelter syndrome, Kallmann syndrome)
- Developmental endocrine disorders
Action: Specialist referral recommended
Secondary Erectile Dysfunction (greater than 90%)
Previously normal function that has deteriorated. Proceed with standard differential diagnosis below.
Key question: Was onset gradual or sudden?
- Gradual onset: Suggests organic cause (vascular, metabolic)
- Sudden onset: Suggests psychogenic, medication-related, or neurological cause
Organic Causes of Erectile Dysfunction
| Probability | Category | Specific Conditions | Key Features |
|---|---|---|---|
| COMMON (approximately 70% of organic cases) | Vasculogenic | Atherosclerosis, hypertension, dyslipidemia, diabetes mellitus (vascular component) | Gradual onset; absent morning erections; cardiovascular risk factors present; age typically greater than 50 |
| COMMON | Diabetes mellitus | Type 2 diabetes (most common), Type 1 diabetes | Affects 50-75% of diabetic men; combines vascular and neurogenic mechanisms; may be presenting symptom of diabetes |
| COMMON | Medication-induced | Antihypertensives, antidepressants, antiandrogens, opioids | Temporal relationship to starting medication; may affect libido and/or erection depending on drug |
| LESS COMMON (approximately 20%) | Neurogenic | Diabetic neuropathy, multiple sclerosis, Parkinson’s disease, spinal cord injury, post-surgical (prostatectomy, colorectal surgery) | Associated neurological symptoms; may have preserved libido; surgical cases have clear temporal relationship |
| LESS COMMON | Hormonal | Hypogonadism (primary or secondary), hyperprolactinemia, thyroid disorders | Reduced libido is prominent; fatigue; may have other hormonal symptoms; check testosterone in all patients |
| LESS COMMON | Anatomical | Peyronie’s disease, penile fibrosis, congenital curvature | Penile deformity; palpable plaque; pain during erection; may cause venous leak |
| UNCOMMON (approximately 10%) | Post-traumatic | Pelvic fracture with urethral injury, perineal trauma, penile fracture | Clear history of trauma; sudden onset; may have associated urological injury |
| UNCOMMON | Venous leak | Primary venogenic erectile dysfunction, secondary to corporal fibrosis | Can achieve erection but cannot maintain it; poor response to PDE5 inhibitors; may require specialized testing |
Psychogenic Causes of Erectile Dysfunction
Key Point: Pure psychogenic erectile dysfunction accounts for 10-20% of cases, but psychological factors contribute to the majority of cases even when an organic cause is present. Always assess for psychological components.
| Category | Specific Conditions | Key Features | Distinguishing Clues |
|---|---|---|---|
| Performance anxiety | Fear of failure, pressure to perform, new partner anxiety | Sudden onset; situational; preserved morning erections; erection possible with masturbation | Often follows single episode of failure; creates self-perpetuating cycle |
| Depression | Major depressive disorder, dysthymia | Reduced libido prominent; anhedonia; sleep disturbance; may be bidirectional relationship | Screen with PHQ-2/PHQ-9; antidepressants may also contribute |
| Anxiety disorders | Generalized anxiety disorder, social anxiety, obsessive-compulsive disorder | Sympathetic overdrive opposes erection; excessive worry about performance | Symptoms present in non-sexual contexts; may have physical anxiety symptoms |
| Relationship factors | Partner conflict, loss of attraction, communication problems, infidelity | Situational to specific relationship; may function with other partners or masturbation | Explore relationship dynamics; consider couples therapy |
| Sexual trauma | History of sexual abuse, prior negative sexual experiences | May be primary or secondary; associated with other psychological symptoms | Sensitive exploration needed; specialist referral often required |
| Stress | Work stress, financial problems, major life changes | Temporal relationship to stressor; may improve when stressor resolves | Explore life circumstances; often coexists with anxiety/depression |
Anatomical/Pathophysiological Approach
Vascular (Arterial Inflow)
Atherosclerosis
Diabetes mellitus
Hypertension
Dyslipidemia
Smoking
Pelvic radiation
Perineal/pelvic trauma
Vascular (Venous Outflow)
Venous leak (veno-occlusive dysfunction)
Peyronie’s disease
Corporal fibrosis
Tunica albuginea abnormality
Age-related smooth muscle loss
Priapism sequelae
Neurological
Diabetic autonomic neuropathy
Multiple sclerosis
Parkinson’s disease
Spinal cord injury/disease
Stroke
Radical prostatectomy
Pelvic surgery (colorectal, vascular)
Hormonal/Endocrine
Hypogonadism (primary or secondary)
Hyperprolactinemia
Hypothyroidism
Hyperthyroidism
Cushing syndrome
Adrenal insufficiency
Drug-Induced Erectile Dysfunction
| Drug or Drug Class | Mechanism | Characteristics | Management |
|---|---|---|---|
| Thiazide diuretics | Unclear; possibly reduced vascular smooth muscle relaxation; zinc depletion | Most commonly implicated antihypertensive; dose-dependent; affects up to 25% of users | Consider switching to angiotensin receptor blocker or calcium channel blocker |
| Beta-blockers (older, non-selective) | Central effects; reduced sympathetic outflow; possible direct penile effect | Atenolol, propranolol more commonly implicated; carvedilol and nebivolol less so | Switch to nebivolol (has nitric oxide potentiating effect) or different class |
| Spironolactone | Antiandrogen effect; blocks testosterone receptors; inhibits testosterone synthesis | Dose-dependent; also causes gynecomastia; common with higher doses | Switch to eplerenone (more selective mineralocorticoid antagonist) |
| Selective serotonin reuptake inhibitors (SSRIs) | Increased serotonin inhibits dopamine and norepinephrine; affects sexual arousal pathway | Affects all phases of sexual function; delayed ejaculation common; reduced libido | Consider bupropion, mirtazapine; drug holidays controversial; add PDE5 inhibitor |
| Serotonin-norepinephrine reuptake inhibitors (SNRIs) | Similar to SSRIs; serotonergic effects predominate | Venlafaxine, duloxetine; similar profile to SSRIs | Similar management to SSRIs |
| Tricyclic antidepressants | Anticholinergic effects; serotonergic effects; alpha-blocking effects | Variable effects; some may improve erectile function initially due to alpha blockade | Consider switching class if problematic |
| Antipsychotics | Dopamine blockade; hyperprolactinemia (especially risperidone, haloperidol) | Reduced libido common; erectile dysfunction; ejaculatory dysfunction | Check prolactin; consider aripiprazole (partial dopamine agonist) |
| 5-alpha reductase inhibitors | Reduced dihydrotestosterone; possible direct effects on penile tissue | Finasteride, dutasteride; affects 3-5% of users; rarely persistent after stopping | Discuss risk before starting; controversial “post-finasteride syndrome” |
| GnRH agonists/antagonists | Medical castration; profound testosterone suppression | Used for prostate cancer; near-universal erectile dysfunction and loss of libido | Expected effect; PDE5 inhibitors less effective without testosterone |
| Opioids (chronic use) | Suppresses hypothalamic-pituitary-gonadal axis; causes hypogonadism | Affects libido and erectile function; common with long-term use | Check testosterone; consider testosterone replacement if indicated; reduce opioid if possible |
| Cimetidine | Antiandrogen effect; weak androgen receptor antagonist | Dose-dependent; less common with other H2 blockers | Switch to proton pump inhibitor or other H2 blocker |
| Digoxin | Structural similarity to estrogen; inhibits sodium-potassium ATPase in smooth muscle | Dose-dependent; gynecomastia may also occur | Check levels; minimize dose; consider alternative if possible |
Recreational Substances and Lifestyle Factors
| Substance | Acute Effects | Chronic Effects | Clinical Notes |
|---|---|---|---|
| Alcohol | Low doses may reduce inhibition; higher doses impair erection (“brewer’s droop”) | Peripheral neuropathy; hypogonadism; liver disease with increased estrogen | Advise moderation; chronic heavy use causes permanent damage |
| Tobacco/Nicotine | Acute vasoconstriction | Accelerated atherosclerosis; endothelial dysfunction; 1.5x increased risk of erectile dysfunction | Smoking cessation improves erectile function; strongest modifiable risk factor |
| Cannabis | Variable; some report enhanced experience, others impaired function | May affect testosterone; cannabinoid receptors present in penile tissue | Evidence mixed; advise moderation |
| Cocaine | May enhance arousal initially; vasoconstriction impairs erection | Associated with priapism; cardiovascular damage | Dangerous with PDE5 inhibitors (cardiovascular risk) |
| Anabolic steroids | May initially improve sexual function | Testicular atrophy; hypogonadism when stopped; may be permanent | Common cause of hypogonadism in younger men; recovery variable |
Age-Related Differential Considerations
| Age Group | Most Likely Causes | Special Considerations |
|---|---|---|
| Under 40 years | Psychogenic (performance anxiety, depression); medication-induced; recreational drugs; primary hypogonadism | Organic causes less common but should not be excluded; may indicate early cardiovascular disease; anabolic steroid use increasingly common |
| 40-60 years | Mixed etiology common; vascular disease emerging; diabetes; medication-induced; stress-related | Erectile dysfunction may be first sign of cardiovascular disease; screen for metabolic syndrome; testosterone decline begins |
| Over 60 years | Vasculogenic predominant; polypharmacy; hypogonadism; post-prostatectomy; partner-related factors | Multiple contributing factors common; partner’s health status important; realistic expectations; cardiovascular safety assessment essential |
Quick Reference: “If You See This, Think This”
| Clinical Clue | Think This First | Next Step |
|---|---|---|
| Preserved morning erections, sudden onset, situational | Psychogenic erectile dysfunction | Explore psychological factors; consider psychosexual therapy |
| Absent morning erections, gradual onset, cardiovascular risk factors | Vasculogenic erectile dysfunction | Cardiovascular risk assessment; fasting glucose and lipids |
| Reduced libido as primary complaint, fatigue, small testes | Hypogonadism | Morning testosterone level; consider LH, FSH, prolactin |
| Temporal relationship to new medication | Drug-induced erectile dysfunction | Review medications; consider trial of alternative agent |
| Known diabetes with peripheral neuropathy symptoms | Diabetic erectile dysfunction (mixed vascular/neurogenic) | Optimize glycemic control; may need higher PDE5 inhibitor doses |
| History of pelvic surgery (prostatectomy, colorectal) | Neurogenic erectile dysfunction (cavernous nerve injury) | Penile rehabilitation protocol; may need intracavernosal therapy |
| Penile curvature, palpable plaque, pain with erection | Peyronie’s disease | Assess disease phase (active vs stable); urology referral |
| Can achieve but not maintain erection | Venous leak (veno-occlusive dysfunction) | May need penile Doppler ultrasound; often poor PDE5 inhibitor response |
| Young patient with primary erectile dysfunction | Congenital/developmental abnormality or severe psychological factors | Specialist referral; comprehensive endocrine and psychological evaluation |
| Galactorrhea, visual field defects, reduced libido | Hyperprolactinemia (pituitary adenoma) | Prolactin level; pituitary MRI if elevated |
6. Diagnostic Investigations
A stepwise, cost-effective approach guided by clinical suspicion
The investigation of erectile dysfunction should be guided by history and physical examination findings. A basic laboratory panel is recommended for all patients to screen for common underlying conditions and assess cardiovascular risk. Additional investigations are reserved for specific clinical indications.
Baseline Investigations for All Patients
| Investigation | Purpose | What to Look For | Practical Points |
|---|---|---|---|
| Fasting glucose or HbA1c | Screen for diabetes mellitus | Fasting glucose ≥7.0 mmol/L (126 mg/dL) or HbA1c ≥6.5% (48 mmol/mol) indicates diabetes | Erectile dysfunction may be presenting symptom of undiagnosed diabetes; HbA1c preferred as does not require fasting |
| Lipid profile | Cardiovascular risk assessment | Total cholesterol, LDL, HDL, triglycerides; dyslipidemia increases vascular erectile dysfunction risk | Part of comprehensive cardiovascular risk assessment; guides statin therapy |
| Morning total testosterone | Screen for hypogonadism | Low if less than 8 nmol/L (230 ng/dL); borderline 8-12 nmol/L (230-350 ng/dL); normal greater than 12 nmol/L (350 ng/dL) | MUST be morning sample (before 10 AM) due to diurnal variation; repeat if low; consider free testosterone if borderline |
| Complete blood count | General health screen; baseline before testosterone | Anemia may cause fatigue and reduced libido; polycythemia baseline before testosterone therapy | Chronic disease may contribute to erectile dysfunction |
| Renal function (creatinine, eGFR) | Screen for chronic kidney disease | Chronic kidney disease associated with erectile dysfunction; affects drug dosing | Important for PDE5 inhibitor dose adjustment if reduced |
| Liver function tests | Screen for liver disease; baseline before medications | Liver disease causes increased estrogen, decreased testosterone | Important for PDE5 inhibitor dosing; hepatic metabolism |
Cardiovascular Risk Assessment
All patients with erectile dysfunction should undergo cardiovascular risk stratification. Use a validated risk calculator (Framingham, QRISK, or equivalent). Erectile dysfunction independently increases cardiovascular risk. Men with erectile dysfunction and no known cardiac disease have similar event rates to men with known coronary artery disease. This is an opportunity for primary prevention.
Second-Line Hormonal Investigations
Order these if morning testosterone is low or borderline, or if clinical suspicion of hormonal disorder is high:
| Investigation | When to Order | Interpretation | Clinical Implications |
|---|---|---|---|
| Repeat morning testosterone | Initial testosterone low or borderline | Confirm hypogonadism; testosterone levels fluctuate | Two low values on separate occasions required to diagnose hypogonadism |
| Free testosterone or bioavailable testosterone | Total testosterone borderline (8-12 nmol/L); obesity; suspected altered sex hormone-binding globulin | More accurate reflection of biologically active testosterone | Sex hormone-binding globulin increases with age, liver disease, hyperthyroidism; decreases with obesity, diabetes |
| Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) | Confirmed low testosterone | High LH/FSH = primary hypogonadism (testicular failure); Low/normal LH/FSH = secondary hypogonadism (pituitary/hypothalamic) | Secondary hypogonadism requires pituitary evaluation; primary hypogonadism suggests testicular cause |
| Prolactin | Low testosterone with low/normal LH; symptoms suggesting hyperprolactinemia; medications known to raise prolactin | Elevated prolactin suppresses gonadotropins; mild elevation may be medication-induced; significantly elevated suggests adenoma | Prolactin greater than 2x upper limit of normal warrants pituitary MRI |
| Thyroid function tests (TSH, free T4) | Symptoms of thyroid disorder; otherwise low threshold to check | Hypothyroidism: elevated TSH, low T4; Hyperthyroidism: suppressed TSH, elevated T4 | Both conditions can affect sexual function; easily treatable |
| Sex hormone-binding globulin (SHBG) | Need to calculate free testosterone; obesity; liver disease suspected | Used to calculate free testosterone; affected by multiple conditions | Low SHBG common in obesity and diabetes; high SHBG in liver disease and aging |
| Estradiol | Gynecomastia; obesity; suspected aromatase excess | Elevated in obesity (adipose tissue contains aromatase); liver disease | High estradiol may contribute to erectile dysfunction and feminization |
Targeted Investigations by Suspected Etiology
If Suspecting Vasculogenic Erectile Dysfunction
First-Line (Primary Care)
- Cardiovascular risk assessment: Calculate 10-year cardiovascular risk using validated tool
- ECG: If cardiovascular disease suspected or before PDE5 inhibitor initiation in higher-risk patients
- Blood pressure: Confirm hypertension if elevated
Second-Line (Specialist)
- Penile Doppler ultrasound: Assesses arterial inflow and venous leak; peak systolic velocity less than 25 cm/s suggests arterial insufficiency; end-diastolic velocity greater than 5 cm/s suggests venous leak
- Exercise stress testing: If cardiac symptoms or high-risk before initiating PDE5 inhibitor
- Coronary angiography: Not for erectile dysfunction per se, but if cardiac disease suspected
If Suspecting Neurogenic Erectile Dysfunction
First-Line
- Clinical neurological examination: Peripheral sensation, reflexes, bulbocavernosus reflex
- HbA1c: Diabetic neuropathy is most common neurogenic cause
Second-Line (Specialist)
- Nerve conduction studies/EMG: If peripheral neuropathy suspected and confirmation needed
- MRI spine: If spinal cord pathology suspected (cauda equina, multiple sclerosis)
- Biothesiometry: Quantitative vibration perception testing
If Suspecting Psychogenic Erectile Dysfunction
Screening Tools
- PHQ-9: Depression screening; score ≥10 suggests moderate depression
- GAD-7: Anxiety screening; score ≥10 suggests moderate anxiety
- Relationship assessment: Validated tools available if indicated
Confirmatory (Rarely Needed)
- Nocturnal penile tumescence testing: Documents erections during sleep; normal result confirms psychogenic cause; rarely performed in modern practice
- Rigiscan testing: Quantitative measurement of nocturnal erections
If Suspecting Peyronie’s Disease
First-Line
- Clinical examination: Palpation for plaque; patient photographs of erect penis to document curvature
- History: Phase of disease (active with pain vs stable)
Second-Line (Urology)
- Penile ultrasound: Documents plaque size and location; calcification
- Penile Doppler: Assess for associated veno-occlusive dysfunction
- Goniometry: Objective measurement of curvature angle
Specialized Investigations (Urology/Sexual Medicine Referral)
| Investigation | Indication | What It Assesses | Clinical Utility |
|---|---|---|---|
| Intracavernosal injection test | Assess erectile capacity; poor response to PDE5 inhibitors; before penile prosthesis | Direct smooth muscle relaxation; bypasses neurological and hormonal factors | Full erection with injection suggests intact veno-occlusive mechanism; also used therapeutically |
| Penile Doppler ultrasound (with injection) | Distinguish arterial insufficiency from venous leak; pre-surgical planning | Peak systolic velocity (arterial inflow), end-diastolic velocity (venous leak), resistive index | PSV less than 25 cm/s = arterial disease; EDV greater than 5 cm/s = venous leak |
| Dynamic infusion cavernosometry/cavernosography (DICC) | Confirm venous leak when surgery considered; rarely performed | Flow required to maintain erection; identifies venous leak sites | Largely replaced by Doppler; used pre-operatively for venous surgery |
| Penile angiography | Young patients with traumatic arterial injury; pre-operative planning for arterial bypass | Arterial anatomy; site of obstruction | Rarely indicated; reserved for young patients with focal traumatic lesions amenable to surgery |
| Nocturnal penile tumescence (NPT) testing | Distinguish organic from psychogenic when unclear; medicolegal purposes | Documents presence and quality of nocturnal erections during REM sleep | Normal NPT essentially excludes organic cause; largely replaced by clinical assessment |
Empiric Treatment as a Diagnostic Tool
Therapeutic Trial Approach
In many cases, response to treatment provides diagnostic information. This practical approach is supported by guidelines and is often more cost-effective than extensive investigation.
- PDE5 inhibitor trial: Good response suggests adequate vascular function and intact neurological pathway; poor response may indicate severe vascular disease, neurogenic cause, or venous leak
- Testosterone replacement trial: If testosterone low/borderline with symptoms; improvement in libido and erectile function supports hypogonadism diagnosis (reassess at 3-6 months)
- Medication switch: If temporal relationship to medication suspected; improvement after switching supports drug-induced cause
- Psychosexual therapy trial: If psychogenic factors suspected; improvement supports diagnosis
Practical Investigation Algorithm
Step-by-Step Approach:
- All patients: Fasting glucose/HbA1c, lipid profile, morning testosterone, renal function, liver function tests
- If testosterone low: Repeat morning testosterone; if confirmed low, check LH, FSH, prolactin
- If prolactin elevated or secondary hypogonadism: Pituitary MRI
- Cardiovascular risk stratification: Calculate risk score; ECG if indicated
- Initiate first-line treatment (PDE5 inhibitor if not contraindicated)
- If treatment fails: Reassess diagnosis; consider specialist referral for penile Doppler, intracavernosal injection testing
Prostate-Specific Antigen (PSA) Consideration
Before testosterone replacement therapy: PSA should be checked as testosterone may stimulate growth of occult prostate cancer. Urology referral recommended if PSA elevated or abnormal digital rectal examination. PSA is not routinely required for evaluation of erectile dysfunction itself but is part of pre-testosterone assessment.
Investigations Not Routinely Recommended
| Investigation | Why Not Routine | When It May Be Indicated |
|---|---|---|
| Penile Doppler ultrasound | Does not change initial management; PDE5 inhibitor trial provides similar information | Poor response to treatment; considering surgical intervention; medicolegal cases |
| Nocturnal penile tumescence testing | Rarely changes management; clinical assessment usually sufficient | Diagnostic uncertainty between organic and psychogenic; medicolegal cases |
| Hormone panel beyond testosterone | Low yield if testosterone normal; expensive | Testosterone low or clinical suspicion of specific endocrine disorder |
| Routine neurological investigations | Clinical examination and history usually sufficient | Neurological symptoms or signs; suspected spinal pathology |
7. Pattern Recognition and Clinical Decision-Making
Practical algorithms and decision pathways
Step 1: Is This Urgent?
| Clinical Scenario | Urgency Level | Immediate Action |
|---|---|---|
| Priapism (painful erection lasting more than 4 hours) | EMERGENT | Immediate urology referral; ischemic priapism is urological emergency; aspiration and phenylephrine injection within 4-6 hours to prevent permanent damage |
| Erectile dysfunction with new neurological symptoms (leg weakness, urinary retention, saddle anesthesia) | EMERGENT | Urgent MRI spine; possible cauda equina syndrome; neurosurgical consultation |
| Erectile dysfunction with unstable angina or recent myocardial infarction | EMERGENT | Cardiac stabilization first; defer erectile dysfunction treatment until cardiovascularly stable (minimum 2 weeks post-MI, ideally 6-8 weeks) |
| Erectile dysfunction with severe depression and suicidal ideation | URGENT | Psychiatric evaluation priority; address mental health crisis first; erectile dysfunction treatment can follow stabilization |
| Peyronie’s disease in active phase (painful erections, progressing curvature) | URGENT | Urology referral within 2-4 weeks; early intervention may limit progression; medical therapy most effective in active phase |
| Suspected pituitary tumor (visual symptoms, severe headache, hyperprolactinemia) | URGENT | Pituitary MRI; endocrinology referral; visual field testing if visual symptoms |
| Typical erectile dysfunction without red flags | ROUTINE | Comprehensive evaluation; baseline investigations; initiate first-line treatment; follow-up in 4-8 weeks |
Step 2: Cardiovascular Risk Stratification
Essential Before Treatment
Sexual activity is equivalent to mild-to-moderate physical exertion (3-5 metabolic equivalents, similar to climbing 2-3 flights of stairs). All patients must be assessed for cardiovascular fitness before initiating treatment for erectile dysfunction.
| Risk Category | Patient Characteristics | Management Approach |
|---|---|---|
| LOW RISK | Asymptomatic, fewer than 3 cardiovascular risk factors; controlled hypertension; mild stable angina; successful revascularization; uncomplicated past MI (more than 6-8 weeks); mild valvular disease; able to achieve 5-6 METs on stress testing without symptoms | Safe to initiate erectile dysfunction treatment; manage cardiovascular risk factors; routine follow-up |
| INTERMEDIATE RISK | 3 or more cardiovascular risk factors; moderate stable angina; recent MI (2-6 weeks); LVH; heart failure (NYHA Class II); history of stroke or TIA; peripheral arterial disease | Requires further cardiac evaluation before treatment; exercise stress test or cardiology consultation; restratify to low or high risk before treatment |
| HIGH RISK | Unstable or refractory angina; uncontrolled hypertension; heart failure (NYHA Class III-IV); recent MI (less than 2 weeks); high-risk arrhythmias; hypertrophic obstructive cardiomyopathy; moderate-to-severe valvular disease | Sexual activity should be deferred until cardiac condition stabilized and evaluated by cardiologist; erectile dysfunction treatment contraindicated until restratified |
Step 3: Classify by Onset Pattern
Gradual Onset
Suggests: Vasculogenic, metabolic, or hormonal cause
Action: Full metabolic workup; cardiovascular risk assessment; morning testosterone; proceed to Algorithm A
Sudden Onset
Suggests: Psychogenic, medication-induced, or post-surgical/traumatic
Action: Detailed medication review; psychosocial assessment; neurological evaluation if trauma/surgery; proceed to Algorithm B
Step 4: Follow the Appropriate Algorithm
Algorithm A: Gradual Onset Erectile Dysfunction
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Age over 50, cardiovascular risk factors, absent morning erections, normal testosterone | Vasculogenic erectile dysfunction | Cardiovascular risk modification; lifestyle counseling; PDE5 inhibitor first-line; cardiovascular follow-up |
| Known diabetes, peripheral neuropathy symptoms, gradual progression | Diabetic erectile dysfunction (mixed mechanism) | Optimize glycemic control; PDE5 inhibitor (may need higher doses); consider testosterone if low |
| Low testosterone, reduced libido, fatigue, decreased energy | Hypogonadism | Confirm with repeat testosterone; check LH/FSH/prolactin; testosterone replacement if confirmed; reassess erectile function after 3-6 months |
| Normal testosterone, cardiovascular risk factors controlled, still symptomatic | Vasculogenic with possible additional factors | Trial PDE5 inhibitor with adequate dosing and attempts; if failure, consider penile Doppler or specialist referral |
| Progressive curvature, palpable plaque, pain during erection | Peyronie’s disease | Assess disease phase; urology referral; medical therapy if active phase; surgical options if stable |
Algorithm B: Sudden Onset Erectile Dysfunction
| Clinical Scenario | Most Likely Diagnosis | Action |
|---|---|---|
| Recent new medication (especially antihypertensive, antidepressant, or antiandrogen) | Medication-induced erectile dysfunction | Review medication timing; consider switch to alternative agent; reassess in 4-8 weeks; may add PDE5 inhibitor |
| Preserved morning erections, situational, performance anxiety, new relationship | Psychogenic erectile dysfunction | Reassurance; psychosexual therapy; may use PDE5 inhibitor to break anxiety cycle; address relationship factors |
| Following radical prostatectomy or pelvic surgery | Post-surgical neurogenic erectile dysfunction | Penile rehabilitation protocol; early PDE5 inhibitor use; may require intracavernosal injection therapy; realistic expectations counseling |
| Following pelvic trauma or fracture | Post-traumatic erectile dysfunction | Assess for urethral injury; penile Doppler if vascular injury suspected; urology referral; may need surgical repair in young patients |
| Associated with significant life stress, depression symptoms, relationship conflict | Psychogenic with possible depression | Screen for depression (PHQ-9); consider antidepressant (preferably erectile-sparing); couples therapy if relationship issues; PDE5 inhibitor may help |
Step 5: Treatment Selection Algorithm
First-Line Treatment Selection:
- Lifestyle modification for ALL patients: Weight loss if obese, smoking cessation, exercise, alcohol moderation, optimize comorbidities
- Address reversible causes: Stop offending medications, treat hypogonadism, manage psychological factors
- PDE5 inhibitor: First-line pharmacotherapy for most patients (if no contraindications)
- If PDE5 inhibitor contraindicated or fails: Proceed to second-line options
| Patient Scenario | Recommended First-Line | Considerations |
|---|---|---|
| Typical erectile dysfunction, no contraindications, wants on-demand use | Sildenafil or vardenafil (shorter acting) | Take 30-60 minutes before activity; avoid high-fat meals; start with standard dose |
| Wants spontaneity, frequent sexual activity | Tadalafil daily (2.5-5 mg) or as needed (10-20 mg) | 36-hour duration allows flexibility; daily dosing provides continuous effect; also treats benign prostatic hyperplasia symptoms |
| Concurrent benign prostatic hyperplasia/lower urinary tract symptoms | Tadalafil 5 mg daily | Only PDE5 inhibitor approved for both conditions; single medication for both |
| Taking nitrates (any form) | PDE5 inhibitors CONTRAINDICATED | Refer for vacuum device, intracavernosal injection, or prosthesis consideration; cardiology consultation about nitrate necessity |
| Low testosterone with erectile dysfunction | Testosterone replacement first | Reassess erectile function after 3-6 months of testosterone; add PDE5 inhibitor if erectile dysfunction persists |
| Psychogenic erectile dysfunction | Psychosexual therapy ± PDE5 inhibitor | PDE5 inhibitor can break performance anxiety cycle; address underlying psychological factors |
| Post-prostatectomy | PDE5 inhibitor (early, scheduled); consider intracavernosal injection | Penile rehabilitation important; response depends on nerve-sparing status; may need escalation to injections |
PDE5 Inhibitor Selection Guide
| Drug | Onset | Duration | Food Effect | Key Considerations |
|---|---|---|---|---|
| Sildenafil | 30-60 minutes | 4-6 hours | Delayed by fatty food | Most clinical experience; lower cost (generic available); standard starting dose 50 mg |
| Tadalafil | 30-45 minutes (may work up to 36 hours) | Up to 36 hours | No significant effect | Longest duration; daily dosing option; approved for benign prostatic hyperplasia; starting dose 10 mg as needed or 2.5-5 mg daily |
| Vardenafil | 25-60 minutes | 4-6 hours | Delayed by fatty food | Similar to sildenafil; orodispersible form available; avoid with QT-prolonging drugs; starting dose 10 mg |
| Avanafil | 15-30 minutes | 4-6 hours | Minimal effect | Fastest onset; more selective for PDE5; may have fewer side effects; starting dose 100 mg |
“What Do I Do If…” Decision Reference
| Clinical Situation | Immediate Action | Next Step |
|---|---|---|
| Patient is taking nitrates | Do NOT prescribe PDE5 inhibitor | Cardiology consultation to assess if nitrates can be stopped; if nitrates essential, discuss non-PDE5 options (vacuum device, injection, prosthesis) |
| Patient takes alpha-blocker for benign prostatic hyperplasia | Can use PDE5 inhibitor with caution | Start PDE5 inhibitor at lowest dose; ensure alpha-blocker dose is stable; advise about orthostatic hypotension risk; tadalafil may be preferred (also treats benign prostatic hyperplasia) |
| PDE5 inhibitor not working after 4-6 attempts | Reassess: correct use? adequate dosing? adequate stimulation? | Try maximum dose; try different PDE5 inhibitor; check testosterone; consider specialist referral for second-line options |
| Testosterone is low | Confirm with repeat morning level; check LH/FSH/prolactin | If confirmed hypogonadism, initiate testosterone replacement; reassess erectile function at 3-6 months; add PDE5 inhibitor if needed |
| Patient has Peyronie’s disease with erectile dysfunction | Assess disease phase and severity | Urology referral; PDE5 inhibitor may help erectile dysfunction component; definitive treatment may require surgery for curvature |
| Young patient (under 40) with erectile dysfunction | Thorough evaluation; higher suspicion for psychogenic cause | Screen for depression/anxiety; check testosterone; inquire about recreational drugs/anabolic steroids; full cardiovascular workup (may indicate early vascular disease) |
| Patient requests testosterone but level is normal | Explain that testosterone replacement not indicated for normal levels | Investigate other causes; testosterone replacement in eugonadal men is not effective and has risks; address underlying cause |
| Erectile dysfunction with ejaculatory dysfunction | Clarify the specific problem (premature ejaculation, delayed ejaculation, anejaculation) | May have different causes; may need combined treatment approach; SSRIs for premature ejaculation may worsen erectile dysfunction |
Troubleshooting Refractory Erectile Dysfunction
Before Declaring PDE5 Inhibitor Failure, Ask:
- Was the medication used correctly? Adequate time before activity (30-60 minutes for most); not taken with heavy meal (except tadalafil); adequate number of attempts (at least 4-6)
- Was the dose adequate? Many patients need maximum dose; dose titration attempted?
- Was there adequate sexual stimulation? PDE5 inhibitors require arousal to work; not automatic erection pills
- Were different PDE5 inhibitors tried? Patients may respond to one but not another
- Is testosterone level adequate? Hypogonadism reduces PDE5 inhibitor efficacy; must be addressed
- Are psychological factors adequately addressed? Performance anxiety may persist; psychosexual therapy needed
- Is there undiagnosed venous leak? Consider penile Doppler; poor response to PDE5 inhibitors is characteristic
- Is the underlying disease severe? Severe diabetes, post-radical prostatectomy may need second-line therapy
When to Refer to Urology/Sexual Medicine Specialist
Refer Early
- Primary erectile dysfunction (never achieved erection)
- Peyronie’s disease
- Post-surgical erectile dysfunction (prostatectomy)
- Penile trauma or anatomical abnormality
- Young patient (under 40) with organic erectile dysfunction
- Suspected vascular steal syndrome
Refer After Initial Management
- PDE5 inhibitor failure after adequate trials
- Contraindication to PDE5 inhibitors
- Interest in second-line therapies (injections, vacuum devices)
- Consideration for penile prosthesis
- Complex cases with multiple contributing factors
- Need for specialized testing (penile Doppler)
8. Clinical Pearls and Pitfalls
Practical wisdom — learn from successes and avoid common mistakes
Must-Know Clinical Pearls
Erectile dysfunction as cardiovascular sentinel: Erectile dysfunction precedes coronary artery disease symptoms by an average of 2-5 years. Every patient with erectile dysfunction should undergo cardiovascular risk assessment — this is an opportunity for primary prevention.
Morning erections tell the story: Preserved morning erections strongly suggest psychogenic etiology; absent morning erections point toward organic disease. This simple question provides valuable diagnostic information.
Always check testosterone: A morning testosterone level should be checked in all patients with erectile dysfunction. Hypogonadism is common, treatable, and reduces the effectiveness of PDE5 inhibitors if left unaddressed.
PDE5 inhibitors need arousal to work: These are not “automatic erection pills.” Sexual stimulation is required for the medication to be effective. Educate patients that the medication enhances natural response, not replaces it.
Give PDE5 inhibitors a fair trial: Many patients declare failure too quickly. Recommend at least 4-6 attempts with proper technique before concluding the medication doesn’t work. Try maximum dose and different PDE5 inhibitors before declaring failure.
Mixed etiology is the rule: Most patients have both organic and psychogenic components. Even when organic disease is present, performance anxiety typically develops as a secondary problem. Address both components for optimal outcomes.
Lifestyle modification works: Weight loss, exercise, smoking cessation, and alcohol moderation can significantly improve erectile function. These should be recommended to all patients alongside pharmacotherapy.
Tadalafil for comorbid benign prostatic hyperplasia: Daily tadalafil 5 mg is approved for both erectile dysfunction and benign prostatic hyperplasia symptoms. Consider this in patients with both conditions — one pill treats both.
Critical Pitfalls to Avoid
Prescribing PDE5 inhibitors to patients on nitrates: This combination can cause life-threatening hypotension. Always ask about ALL nitrate use including sublingual nitroglycerin, isosorbide, nitroglycerin patches, and recreational “poppers” (amyl nitrite).
Missing the cardiovascular risk: Erectile dysfunction is a marker for systemic vascular disease. Failing to assess and address cardiovascular risk factors is a missed opportunity for prevention and potentially dangerous.
Forgetting to check testosterone: Hypogonadism is a common and treatable cause. Prescribing PDE5 inhibitors without checking testosterone may lead to treatment failure that could have been avoided.
Ignoring medication causes: Many common medications cause or contribute to erectile dysfunction. Failure to perform a thorough medication review may miss an easily reversible cause.
Neglecting the psychological component: Even with clear organic etiology, psychological factors almost always contribute. Treating only the organic component without addressing performance anxiety, depression, or relationship issues leads to suboptimal outcomes.
Starting testosterone in eugonadal men: Testosterone replacement is only indicated for confirmed hypogonadism. Giving testosterone to men with normal levels is ineffective and carries risks (erythrocytosis, potential prostate stimulation).
Forgetting the partner: Erectile dysfunction affects couples, not just individuals. The partner’s health, expectations, and relationship dynamics are important. Failing to address these factors reduces treatment success.
Not counseling on proper PDE5 inhibitor use: Patients need to understand timing, food effects, need for stimulation, and adequate trial numbers. Poor outcomes often result from improper use rather than medication failure.
Key Takeaways
- Erectile dysfunction affects approximately 40% of men at age 40 and nearly 70% by age 70; it is extremely common and significantly impacts quality of life
- Erectile dysfunction is an independent marker for cardiovascular disease, preceding coronary events by 2-5 years; use this presentation as an opportunity for cardiovascular risk assessment and prevention
- The etiology is usually multifactorial with organic and psychogenic components; vasculogenic causes account for approximately 70% of organic cases
- History is the most important diagnostic tool: onset pattern (gradual vs sudden), morning erections, and situational factors help distinguish organic from psychogenic causes
- Basic workup for all patients includes fasting glucose/HbA1c, lipid profile, and morning testosterone; additional investigations are guided by clinical findings
- Cardiovascular risk stratification is essential before treatment; ensure patients can safely engage in sexual activity (equivalent to climbing 2-3 flights of stairs)
- PDE5 inhibitors are first-line pharmacotherapy for most patients; they are effective, safe, and well-tolerated when used appropriately and without contraindications
- Absolute contraindication: concurrent nitrate use (any form); always ask specifically about all nitrates including recreational “poppers”
- Ensure adequate PDE5 inhibitor trial: correct timing, appropriate dose, adequate attempts (4-6), adequate stimulation, and trial of different agents before declaring failure
- Address modifiable factors in all patients: smoking cessation, weight loss, exercise, alcohol moderation, optimize diabetes and hypertension
- Treat hypogonadism if present; testosterone replacement improves libido and may enhance response to PDE5 inhibitors
- Refer to urology/sexual medicine specialist for PDE5 inhibitor failure, complex cases, Peyronie’s disease, post-prostatectomy erectile dysfunction, or consideration of second-line therapies
Quick Reference Algorithm
Systematic Approach to Erectile Dysfunction:
- Take a comprehensive history: Use the “ERECTION” mnemonic; differentiate organic from psychogenic; identify red flags; review medications
- Perform focused physical examination: Cardiovascular assessment, genitourinary examination, focused neurological examination
- Order baseline investigations: Fasting glucose/HbA1c, lipid profile, morning testosterone, basic metabolic panel
- Assess cardiovascular risk: Stratify as low, intermediate, or high risk; address accordingly before treatment
- Address reversible causes: Stop offending medications, treat hypogonadism, recommend lifestyle modifications
- Initiate first-line treatment: PDE5 inhibitor (if no contraindications); counsel on proper use
- Follow up and reassess: Evaluate response at 4-8 weeks; optimize treatment; address psychological factors
- Escalate if needed: Try different PDE5 inhibitor or maximum dose; refer to specialist for second-line options if failure
Critical Drug Interactions Quick Reference
| Drug/Class | Interaction with PDE5 Inhibitors | Recommendation |
|---|---|---|
| Nitrates (all forms) | Severe, potentially fatal hypotension | ABSOLUTE CONTRAINDICATION — never prescribe together |
| Alpha-blockers | Additive hypotensive effect | Use with caution; start PDE5 inhibitor at lowest dose; ensure stable alpha-blocker dose |
| Strong CYP3A4 inhibitors (ritonavir, ketoconazole) | Increased PDE5 inhibitor levels | Reduce PDE5 inhibitor dose significantly; avoid or use minimum dose |
| Recreational “poppers” (amyl/butyl nitrite) | Same as medical nitrates — severe hypotension | ABSOLUTE CONTRAINDICATION — counsel patients specifically about this |